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Serum Gamma-Glutamyltransferase Concentration Correlates 
with Framingham Risk Score in Koreans
Gamma-glutamyltransferase (GGT) is a novel coronary artery disease (CAD) risk factor, but 
its use as an independent factor for CAD risk prediction remains unclear in Asian 
population. This study examined the association between serum GGT concentration and 
Framingham risk score (FRS) in the Korean population. This cross-sectional study was 
performed on 30,710 Koreans. Besides FRS, body mass index, fasting blood glucose, liver 
enzymes, lipid profile, uric acid and high sensitive C-reactive protein data were used. The 
study subjects were grouped into quartiles according to the levels of GGT. Analyses relating 
GGT to FRS  ≥ 20% utilized multiple confounders adjusted logistic regression. Positive 
correlations were established between log-transformed GGT concentration and FRS 
(r = 0.38; P < 0.001). Increasing the quartile of serum GGT concentration was significantly 
associated with linear increasing trends in FRS (P-trend < 0.001). Compared to the lowest 
baseline GGT category, age-gender adjusted odd ratios for FRS ≥ 20% were significantly 
increased from the lowest to highest GGT quartiles; these results remained significantly 
after adjustments for multiple confounders. Increased GGT concentration is associated 
with the increase in FRS. Serum GGT may be helpful to predict the future risk of CAD.
Key Words: Gamma-Glutamyltransferase; Framingham Risk Score; Oxidative Stress
Kyu-Nam Kim, Kwang-Min Kim,  
Duck-Joo Lee and Nam-Seok Joo
Department of Family Practice and Community 
Health, Ajou University School of Medicine, Suwon, 
Korea
Received: 6 May 2011
Accepted: 10 July 2011
Address for Correspondence:
Nam-Seok Joo, MD
Department of Family Practice and Community Health,  
Ajou University School of Medicine, 164 Worldcup-ro, 
Youngtong-gu, Suwon 443-721, Korea 
Tel: +82.31-219-5324, Fax: +82.31-219-5218
E-mail: jchcmc@hanmail.net
http://dx.doi.org/10.3346/jkms.2011.26.10.1305  •  J Korean Med Sci 2011; 26: 1305-1309
ORIGINAL ARTICLE
Cardiovascular Disorders
INTRODUCTION
Cardiovascular diseases such as coronary artery disease (CAD) 
and stroke are among the leading causes of death in Asian pop-
ulations as well as in Western countries (1). Oxidative stress is 
thought to play an important role in the progression of athero-
sclerosis (2, 3). Several studies have implicated gamma glutam-
yltransferase (GGT) as a biomarker of oxidative stress and expo-
sure to xenobiotics (4, 5). Parallel evidence from epidemiologi-
cal studies suggest that higher serum GGT is associated with de-
velopment of CAD risk factors, including diabetes, high blood 
pressure (BP) and dyslipidemia (6-9), and metabolic syndrome 
(6). GGT levels are related positively to novel cardiovascular risk 
factors such as C-reactive protein (CRP) and fibrinogen (10), and 
are inversely related to antioxidant levels (11). Increased GGT 
has been linked with mortality attributable to CAD and cerebro-
vascular disease (12, 13). In spite of the clinical impact these in-
creased GGT levels have in western countries, however, it is little 
known the effect of GGT levels in the prediction of the CAD risk 
in Asian population. The Framingham Risk Score (FRS) is a math-
ematic model for predicting CAD during a 10-yr period that has 
become a widely-used clinical tool to guide the delivery of pre-
ventive medicine (14, 15).
  The present study was grounded in the hypothesis that increas-
ing serum GGT is associated with the risk of CAD, calculated 
using FRS modified by the National Cholesterol Education Pro-
gram (NCEP) Adult Treatment Panel III (ATP III) guideline, and 
should be considered as a factor associated with CAD risk pre-
diction. The aim of this study was to examine whether serum 
GGT levels are associated with FRS in Koreans. 
MATERIALS AND METHODS
Study data
From January 2007 to May 2009, data of 42,906 Koreans aged 20-
86 yr who visited the Health Promotion Center, Ajou University 
Hospital, Suwon, Korea, were reviewed for inclusion in the study. 
Medical history, demographics, anthropometric, and laborato-
ry data were collected. Data on cigarette smoking and alcohol 
consumption were collected by a self-reported questionnaire. 
Subjects who, at the time of the survey, had smoked cigarettes 
regularly within the prior year were considered to be current 
smokers and weekly alcohol intake was calculated and then con-
verted to weekly alcohol consumption (grams of ethanol per 
week) by graduated frequency method (16). Of the initial 42,906 
subjects, 9,256 (21.5%) were excluded because of absent data 
for any component of FRS or smoking or alcohol history. We also 
excluded subjects (n = 1,124) with hepatobiliary disease, posi-Kim K-N, et al.  •  Serum Gamma-glutamyltransferase and Framingham Risk Score
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tive tests for antibody to hepatitis B surface antigen, antibody to 
hepatitis B virus core antigen or anti-hepatitis C virus, and pa-
tients (n = 1,012) taking drugs influencing liver function and 
statins or other lipid-lowering drugs, and subjects (n = 804) with 
high sensitive CRP (hs-CRP)  ≥ 10.0 mg/L to preclude any pos-
sible occult inflammatory or infectious disease. Thus, a total of 
30,710 healthy Korean (13,777 females, 16,933 males) were in-
cluded in the final analyses. 
Measurements
Serum GGT was assayed by the standard method recommend-
ed by the International Federation for Clinical Chemistry using 
L-γ-glutamyl-3-carboxy-4-nitroanilide as substrate with a Toshi-
ba 200FR autoanalyzer. Hs-CRP was measured by a high-sensi-
tivity nephelometric method (Dade Behring Marburg GMBH, 
Marburg, Germany). BP was measured using a standard mer-
cury manometer with the participant in a sitting position for 5 
min prior to measurement; the average of two measurements 
was recorded. Hypertension was defined as a systolic BP 140 
mmHg or a diastolic BP 90 mmHg, or the use of antihyperten-
sive medication. Fasting blood specimens were used for mea-
suring lipids, glucose, and liver enzymes. Diabetes was defined 
by fasting blood glucose 126 mg/dL or the use of oral hypogly-
cemic agents or insulin. Body mass index (BMI) was calculated 
as weight (kg) divided by height squared (m
2). 
Statistical analyses
The distribution of GGT values and alcohol consumption were 
right-skewed, therefore a natural log-transformation was ap-
plied. To assess the relationship between biomarkers and the 
individual components of the FRS, Pearson correlation coeffi-
cients relating individual risk factor scores and the total of FRS 
to log-transfomed GGT levels were analyzed. The study subjects 
were grouped into quartiles according to the circulating levels 
of GGT. We examined the mean FRS according to the quartile 
of serum GGT concentration. ANOVA Trend analysis using poly-
nomial contrasts was adapted to perform tests for trend. Fram-
ingham risk equations (14) were used to predict the risk of de-
veloping total coronary disease events (angina, myocardial in-
farction, or coronary heart disease [CHD] death) over the next 
10 yr. Participants were divided into three groups (17): low risk 
( ≤ 9% risk of developing a CHD event over the next 10 yr), in-
termediate risk (10%-20% risk), and high risk ( > 20% risk). For 
analyses relating GGT to high-risk for CAD (10-yr risk  ≥ 20%), 
we constructed adjusted logistic regression analyses that consid-
ered age/gender, age/gender + alcohol consumption + BMI, and 
(age/gender + alcohol consumption + BMI) + novel and conven-
tional risk factors including hs-CRP, diabetes, low density lipo-
protein (LDL) cholesterol and uric acid. Results of group data are 
expressed as mean ± standard deviation (SD). All statistical anal-
yses were performed using SPSS 13.0 software (SPSS, Chicago, IL, 
USA). P  values  < 0.05 were considered statistically significant. 
Ethics statement
All participants agreed to the use of their health check-up results. 
The institutional review board of Ajou University Hospital ap-
proved this study (AJIRB-MED-OBS-09-240). Informed consent 
was waived by the board.
RESULTS
Compared with women, men presented with more CAD risk 
factors such as diabetes mellitus, hypertension, dyslipidemia, 
alcohol consumption and current smoking (Table 1). Therefore, 
the total Framingham point score and 10-yr CAD risk were high-
er in men than in women. The correlation coefficient between 
log-transfomed GGT levels and FRS was r = 0.38 (P < 0.001) in 
the study subjects (Table 2). These positive correlations were of 
consistent in men (r = 0.19; P <  0.001) and women (r = 0.21; P <  
0.001) (data not shown). Serum GGT also was well correlated 
with individual risk factors. The median (range) of the first-to-
fourth quartiles of GGT values was 11.17 (4-14), 18.11 (15-22), 
29.67 (23-39), and 83.46 (≥ 40) IU/L, respectively. Increasing 
the quartile of serum GGT concentration was significantly as-
sociated with linear increasing trends in FRS (P trend < 0.001) 
(Fig. 1). Compared to the lowest baseline GGT category, age-gen-
der adjusted odds ratio (OR) for FRS  ≥ 20% were 3.1, 5.0, and 7.5 
(P for trend < 0.001) in the other three GGT categories (Table 3). 
The relationship remained statistically significant after additional 
Table 1. General characteristics of the study subjects
Characteristics
All patients 
(n = 30,710)
Women  
(n = 13,777)
Men  
(n = 16,933)
Age (yr)   44.7 ± 10.3   44.6 ± 10.9 44.9 ± 9.9
BMI (kg/m
2) 23.6 ± 3.1 22.8 ± 3.1 24.3 ± 2.9
Current smoker, No. (%) 7,684 (25.0)   471(3.4) 7,213 (42.6)
Alcohol (g/week)   62.9 ± 58.9   40.7 ± 44.0   69.2 ± 61.1
SBP (mmHg) 118.4 ± 14.7 115.3 ± 15.3 121.0 ± 13.6
DBP (mmHg)   77.2 ± 11.3   73.2 ± 10.7   80.8 ± 10.6
Hypertension, No. (%) 3,606 (11.8)  1,385 (10.1) 2,221 (13.1)
Total cholesterol (mg/dL) 186.3 ± 33.4 182.6 ± 33.7 189.1 ± 32.9
HDL cholesterol (mg/dL)   53.2 ± 12.9   57.8 ± 13.0   49.3 ± 11.5
LDL cholesterol (mg/dL) 109.4 ± 29.6 107.1 ± 30.2 112.6 ± 30.0
Triglycerides (mg/dL) 112.4 ± 78.9   89.3 ± 61.1 139.0 ± 97.9
AST (IU/L)   23.1 ± 14.2   20.5 ± 11.4   25.3 ± 15.8
ALT (IU/L)   25.3 ± 23.7   18.6 ± 16.7   30.7 ± 26.9
GGT (IU/L)   33.3 ± 48.5   19.0 ± 28.4   44.8 ± 57.5
Fasting blood glucose (mg/dL)   95.5 ± 19.3   92.5 ± 17.0   98.0 ± 20.8
Diabetes, n (%) 1,884 (6.1)   649 (4.7) 1,235 (7.3)
Total Framingham point score   6.3 ± 6.0   5.0 ± 6.7   7.7 ± 5.1
10-yr CAD risk (%)   3.7 ± 4.8   1.1 ± 1.8   6.1 ± 5.6
Data are expressed as mean ± standard deviations (SDs) or as number (percentage). 
BMI, body mass index; SBP, systolic blood pressure; DBD, diastolic blood pressure; 
LDL, low-density lipoprotein; HDL, high-density lipoprotein, AST, aspartate aminotrans-
ferase, ALT, alanine aminotransferase, GGT, gamma-glutamyl transferase; CAD, coro-
nary artery disease.Kim K-N, et al.  •  Serum Gamma-glutamyltransferase and Framingham Risk Score
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adjustments for alcohol consumption and BMI. Further adjust-
ments for known CAD risk factors attenuated this relationship, 
but GGT remained a significant risk factor in a model that in-
cluded hs-CRP, uric acid, LDL cholesterol and diabetes (Table 3).
DISCUSSION
The present data demonstrate that serum GGT levels positively 
correlate with the risk of CAD calculated using the FRS. The as-
sociation was not confounded by alcohol or the other known 
CAD risk factors (LDL cholesterol, BMI, hs-CRP, uric acid and 
diabetes). 
  Although GGT has been widely utilized as a marker for alcohol 
consumption or liver disease (18, 19), a large number of studies 
suggest that GGT is not only a marker for oxidative stress (4, 20) 
but also a relative factor of cardiovascular disease and metabolic 
syndrome (6, 12, 13, 21). Increased oxidative stress and system-
ic inflammation are considered key factors for the progression 
of atherosclerosis and CAD (2, 11-13). Thus, it was hypothesized 
that GGT could be a marker for CAD risk prediction, regardless 
of alcohol consumption. Our data show that, compared to the 
lowest baseline GGT category, the OR of FRS ≥ 20% increased 
significantly with increased serum GGT levels. After adjustment 
for age, gender, alcohol consumption and other known CAD risk 
factors, the relationship between GGT and FRS ≥ 20% remained 
significant. The cut-off of fourth-quartile GGT levels was defined 
as > 40 IU/L. This value is considered an abnormal GGT level 
according to most medical laboratories. The observations that 
the OR of high-risk for CAD by GGT quartile was significantly 
increased within the normal reference range of GGT levels sug-
gest that GGT could be regarded as a risk stratification marker 
of FRS  ≥ 20%, despite the normal reference range.
  What is the possible underlying mechanism to explain the 
observed link between serum GGT levels and CAD risk predic-
tion? First, although the mechanisms that explain the contribu-
tion of GGT to CAD have not been fully elucidated, GGT is relat-
ed to hepatic steatosis (22) and insulin resistance (23), and is a 
predictor of incident diabetes (24) and hypertension (25). These 
results suggest that there is a potential role of GGT-mediated re-
actions in atherogenesis. Indeed, the potential role of GGT in 
promoting plaque formation and evolution has been confirmed 
by the identification of catalytically-active GGT in coronary, ce-
rebral and carotid plaques, colocalized with oxidized LDL and 
CD68+ foam cells (26). Second, GGT activities may also modu-
late the redox status of protein thiols at the cell surface, leading 
to the production of free radicals and reactive oxygen species, 
and LDL oxidation (27, 28). Thus, GGT is considered a factor that 
contributes to oxidative stress pathways in various organ sys-
tems, localizes to atheromatous plaques containing oxidized li-
Table 3. Odds Ratio (OR) for high-risk for CAD (10-yr risk ≥ 20%) according to GGT levelsw
Model
OR (95% CI)
  P for trend
GGT Levels (IU/L)
Q1 (≤ 14) (n = 7,916) Q2 (15-22) (n = 7,632) Q3 (23-39) (n = 7,678) Q4 ( ≥ 40) (n = 7,464)  
Model 1 1 3.1 (1.7-5.5) 5.0 (2.8-8.7) 7.5 (4.3-13.1) < 0.001
Model 2 1 2.6 (1.0-6.9)   4.5 (1.8-11.5) 7.9 (3.1-19.9) < 0.001
Model 3 1   2.9 (0.6-13.0)   3.9 (0.9-16.9) 5.9 (1.3-25.8) < 0.001
Model 1, after adjustment for age and gender; Model 2, model 1 plus after adjustment for log-transfomed weekly alcohol consumption and body mass index; Model 3, model 2 
plus adjustment for hs-CRP, uric acid, LDL cholesterol and diabetes. CAD, coronary artery disease; GGT, gamma glutamyltransferase; Q1, 1st quartile; Q2, 2nd quartile; Q3, 3rd 
quartile; Q4, 4th quartile. CI, confidence interval.
Table 2. Pearson correlation coefficients relating individual components and the total 
score of Framingham point to log-transfomed GGT concentration
Variables
Correlation  
coefficient
P value
Age score 0.10 < 0.001
Total cholesterol score 0.16 < 0.001
Smoking score 0.30 < 0.001
HDL cholesterol score 0.21 < 0.001
Systolic BP score 0.05 < 0.001
Total Framingham point score 0.33 < 0.001
10-yr CAD risk 0.38 < 0.001
GGT, gamma glutamyltransferase; HDL, high-density lipoprotein; BP, blood pressure; 
CAD, coronary artery disease.
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Fig. 1. The relationship between the 10-yr CAD risk and the quartile of serum GGT 
concentration. Increasing quartiles of serum GGT concentration are significantly as-
sociated with linear increasing trends in 10-yr CAD risk (P trend < 0.001). Vertical 
bar indicates 95% confidence interval. White circle indicates the mean. Kim K-N, et al.  •  Serum Gamma-glutamyltransferase and Framingham Risk Score
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poprotein, and is proinflammatory, further implicating this pro-
tein in atherogenesis (29, 30). These observations may explain 
the finding of an association between serum GGT levels and 
CAD risk prediction.
  This study has several strengths and limitations. One of the 
strengths is the large scale of the study, with subjects of both gen-
der and all age groups. Therefore, the results can be generalized 
into the entire Korean population. Second, we used the catego-
ries of the estimated 10-yr CAD risk calculated by using the NCEP 
ATP III, which is considered the current standard for prediction 
of CAD risk. But, the present study was cross-sectional and we 
did not investigate oxidative stress markers, and thus could not 
examine any association of oxidative stress with serum GGT 
levels. 
  In conclusion, the present study demonstrates that serum GGT 
levels are associated with the estimated 10-yr CAD risk calcu-
lated by using NCEP ATP III in Korean. These significant asso-
ciations in serum GGT levels even within the reference range 
appear to have an additional benefit in the prediction of future 
development of CAD. Thus, serum GGT may be helpful to pre-
dict the future risk of CAD. Further longitudinal cohort studies 
are needed to evaluate the predictive value of biomarkers for 
the risk of CAD in Koreans.
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